Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Poseida Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Poseida Therapeutics's position in the market.
Poseida Therapeutics (NASDAQ: PSTX) announced its upcoming addition to the NASDAQ Biotechnology Index, effective December 21, 2020. This inclusion is significant as the NBI tracks the performance of biotechnology and pharmaceutical companies meeting specific eligibility requirements. The company is focused on developing innovative cell and gene therapies through its proprietary gene engineering platforms. This milestone could enhance visibility and prestige for Poseida, potentially benefiting its market performance and investor interest.
Poseida Therapeutics (NASDAQ: PSTX) has appointed Luke Corning, Head of Credit at Pentwater Capital Management, to its Board of Directors. Corning has been a strong supporter of Poseida, investing in its Series C and D financing rounds. His expertise in corporate finance will enhance the Board's capabilities as Poseida advances its pipeline of cell and gene therapies. Additionally, Sean Murphy, a Board member since 2018, will not seek re-election at the 2021 annual meeting. The announcement reflects ongoing strategic development at Poseida in the biopharmaceutical sector.
Poseida Therapeutics (NASDAQ:PSTX) reported promising results from a Phase 1 trial of P-BCMA-101 at the 2020 ASH Annual Meeting. The trial showed enhanced efficacy with a new nanoplasmid manufacturing method, achieving a 67% overall response rate compared to 50% with the standard plasmid. The safety profile remained favorable, with only one case of cytokine release syndrome observed among eight patients. P-BCMA-101 aims to treat relapsed/refractory multiple myeloma, and the company plans to finalize the Phase 2 dose by Q1 2021.
Poseida Therapeutics (Nasdaq: PSTX) reported operational updates and financial results for Q3 2020. The company emphasized advancements in clinical programs and new collaborations. Notably, on November 2, 2020, the FDA lifted a clinical hold on the P-PSMA-101 trial. R&D expenses increased to $27 million, compared to $15.7 million in Q3 2019. Net losses were $34.4 million for the quarter. As of September 30, 2020, cash reserves stood at $341.5 million, bolstered by IPO proceeds of $205.7 million. The firm is progressing with clinical trials across multiple CAR-T product candidates.
Poseida Therapeutics (Nasdaq: PSTX) announced that the FDA has lifted the clinical hold on its Phase 1 study of P-PSMA-101, an autologous CAR-T therapeutic targeting metastatic castration-resistant prostate cancer (mCRPC). The trial will resume immediately, with protocol amendments aimed at enhancing patient compliance and safety. P-PSMA-101 utilizes Poseida's piggyBac DNA Modification System and was initiated in May 2020. The company emphasizes its commitment to innovative gene engineering technologies for developing next-generation therapeutics.
Poseida Therapeutics (NASDAQ:PSTX) has entered a research collaboration and license agreement with TScan Therapeutics to develop T cell receptor (TCR) therapies for COVID-19 treatment. The partnership combines Poseida's allogeneic T cell platform with TScan's TCR findings from convalescent patients. They aim to create cell-based therapies targeting patients with inadequate T cell responses. The agreement grants Poseida access to TScan's TCR data and expertise, although specific financial terms remain undisclosed.
Poseida Therapeutics (Nasdaq: PSTX) has been officially added to the US small-cap Russell 2000 Index effective September 18, 2020. This addition is expected to enhance investor exposure and support the company’s mission to provide innovative cell and gene therapies. With approximately $9 trillion in assets benchmarked against Russell's US indexes, this membership may increase awareness of Poseida's pipeline targeting oncology and orphan genetic diseases. Eric Ostertag, CEO, expressed optimism about the added visibility and potential growth opportunities.
Poseida Therapeutics (Nasdaq: PSTX) announced its presentation of data on CAR-T product candidate optimizations, particularly focusing on P-BCMA-101 for multiple myeloma, at CAR-TCR Digital Week 2020. The proprietary non-viral manufacturing process enhances therapeutic response by producing high percentages of stem cell memory T cells. Preliminary clinical analysis showed a 100% overall response rate with Nanoplasmid-manufactured P-BCMA-101. The FDA has granted RMAT status and orphan drug designation to P-BCMA-101, which is currently in expanded Phase 1 clinical trials.
Poseida Therapeutics (PSTX) provided an operational update and financial results for Q2 2020. The company raised $104.1 million in a Series D financing and $204.8 million from its IPO, enhancing its financial position to support clinical trials.
Notable updates include the completion of a GMP pilot plant for manufacturing and the ongoing enrollment for its P-BCMA-101 clinical trial targeting multiple myeloma. However, the P-PSMA-101 trial was placed on FDA clinical hold following a patient death. R&D expenses increased to $25.2 million, leading to net losses of $30.4 million.